Over the past few years, immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have changed treatment paradigms in many malignancies, and are currently approved for Hodgkin lymphoma. Here, PDCD1 is linked to Hodgkins lymphoma.